Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: A nationwide population-based cohort study

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Thorsteinsson, Kristina ^a   Ladelund, Steen ^a   Jensen Fangel, Søren ^b   Johansen, Isik S ^c   Katzenstein, Terese L ^d   Pedersen, Gitte ^e   Storgaard, Merete ^a   Obel, Niels ^d   Lebech, Anne Mette ^a  

^a Mental Health Services CPH   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Gender differences; HAART; HIV; Modification; Viral suppression

Indexed keywords

ABACAVIR; EFAVIRENZ; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY FAT DISTRIBUTION; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSLIPIDEMIA; ENDOCRINE DISEASE; ETHNICITY; FEMALE; GASTROINTESTINAL TOXICITY; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; POPULATION RESEARCH; PREGNANT WOMAN; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT; THERAPY DELAY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DENMARK; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PREGNANCY; PROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84868659203     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-293     Document Type: Article

References (50)

1. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?. J Acquir Immune Defic Syndr 2000, 24:475-482.
2. Floridia M, Giuliano M, Palmisano L, Vella S. Gender differences in the treatment of HIV infection. Pharmacol Res 2008, 58:173-182. 10.1016/j.phrs.2008.07.007, 18708144.
3. Kempf MC, Pisu M, Dumcheva A, Westfall AO, Kilby JM, Saag MS. Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr 2009, 52:336-341. 10.1097/QAI.0b013e3181b628be, 2783854, 19654551.
4. Puskas CM, Forrest JI, Parashar S, Salters KA, Cescon AM, Kaida A, et al. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep 2011, 8:277-287. 10.1007/s11904-011-0098-0, 21989672.
5. Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, et al. Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther 2011, 16:805-814. 10.3851/IMP1818, 21900712.
6. Ko NY, Lai YY, Liu HY, Ko WC, Chang CM, Lee NY, et al. Gender differences in HIV manifestations at presentation to care and continuity of care among HIV-infected persons in Taiwan. AIDS Care 2011, 23:1254-1263. 10.1080/09540121.2011.564114, 21939404.
7. http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59&Itemid=41. Accessed on March 26th 2012. 26-3-2012. Ref Type: Internet Communication.
8. Soon GG, Min M, Struble KA, Chan-Tack KM, Hammerstrom T, Qi K, et al. Meta-Analysis of Gender Differences in Efficacy Outcomes for HIV-Positive Subjects in Randomized Controlled Clinical Trials of Antiretroviral Therapy (2000-2008). AIDS Patient Care STDS 2012, 26:444-453. 10.1089/apc.2011.0278, 22734949.
9. Finocchario-Kessler S, Sweat MD, Dariotis JK, Trent ME, Kerrigan DL, Keller JM, et al. Understanding high fertility desires and intentions among a sample of urban women living with HIV in the United States. AIDS Behav 2010, 14:1106-1114. 10.1007/s10461-009-9637-8, 19908135.
10. ECDC/WHO HIV/AIDS Surveillance in Europe 2009, Available from: http://www.ecdc.europa.eu/. Accessed on June 28th 2011. 2011. Ref Type: Internet Communication, ECDC/WHO.
11. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007, 146:87-95.
12. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, D'Arminio MA, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-29. 10.1016/S0140-6736(03)13802-0, 12853195.
13. Moore AL, Sabin CA, Johnson MA, Phillips AN. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr 2002, 29:197-202.
14. Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003, 32:452-461. 10.1097/00126334-200304010-00017, 12640206.
15. Nicastri E, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 2005, 19:577-583. 10.1097/01.aids.0000163934.22273.06, 15802976.
16. http://www.dst.dk/da/Statistik/emner/befolkning-og-befolkningsfremskrivning/folketal.aspx. Accessed on September 14th 2012. Webpage in Danish. 14-9-2012. Ref Type: Internet Communication
17. http://www.ssi.dk/Service/Sygdomsleksikon/H/AIDS%20-%20HIV.aspx. Accessed on September 14th 2012. Webpage in Danish. 14-9-2012. Ref Type: Internet Communication.
18. Petersen TS, Andersen SE, Gerstoft J, Thorsteinsson K, Larsen CS, Pedersen G, et al. Adherence to national guidelines for initiation of antiretroviral regimens in HIV patients: a Danish nationwide study. Br J Clin Pharmacol 2011, 72:116-124. 10.1111/j.1365-2125.2011.03935.x, 3141193, 21306418.
19. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sorensen HT. Cohort profile: the Danish HIV cohort study. Int J Epidemiol 2009, 38:1202-1206. 10.1093/ije/dyn192, 18799495.
20. Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Moller A, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002, 35:1541-1548. 10.1086/344769, 12471575.
21. R Development Core Team R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2011, http://www.R-project.org. 2011. Ref Type: Internet Communication, R Development Core Team.
22. Fardet L, Mary-Krause M, Heard I, Partisani M, Costagliola D. Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response. HIV Med 2006, 7:520-529. 10.1111/j.1468-1293.2006.00414.x, 17105511.
23. Murri R, Lepri AC, Phillips AN, Girardi E, Nasti G, Ferrara S, et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr 2003, 34:184-190. 10.1097/00126334-200310010-00008, 14526207.
24. Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005, 38:96-103. 10.1097/00126334-200501010-00017, 15608532.
25. McNaghten AD, Hanson DL, Dworkin MS, Jones JL. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2003, 32:499-505. 10.1097/00126334-200304150-00006, 12679701.
26. Giordano TP, White AC, Sajja P, Graviss EA, Arduino RC, Du-Oppong A, et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr 2003, 32:399-405. 10.1097/00126334-200304010-00009, 12640198.
27. Stone VE. HIV/AIDS in Women and Racial/Ethnic Minorities in the U.S. Curr Infect Dis Rep 2012, 14:53-60. 10.1007/s11908-011-0226-4, 22139589.
28. Stengaard AR, Lazarus JV, Donoghoe MC, Nielsen S, Matic S. Access to highly active antiretroviral therapy (HAART) for women and children in the WHO European Region 2002-2006. AIDS Care 2009, 21:893-902. 10.1080/09540120802537872, 20024746.
29. Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One 2011, 6:e22698. 10.1371/journal.pone.0022698, 3143183, 21799935.
30. Thorsteinsson K, Ladelund S, Jensen-Fangel S, Larsen MV, Johansen IS, Katzenstein TL, et al. Impact of gender on the risk of AIDS-defining illnesses and mortality in Danish HIV-1-infected patients: A nationwide cohort study. Scand J Infect Dis 2012,
31. Hessol NA, Kalinowski A, Benning L, Mullen J, Young M, Palella F, et al. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis 2007, 44:287-294. 10.1086/510488, 17173233.
32. Larsen MV, Omland LH, Gerstoft J, Larsen CS, Jensen J, Obel N, et al. Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study. Addiction 2010, 105:529-535. 10.1111/j.1360-0443.2009.02827.x, 20402997.
33. Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010, 24:1537-1548.
34. Larsen MV, Omland LH, Gerstoft J, Roge BT, Larsen CS, Pedersen G, et al. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study. Scand J Infect Dis 2010, 42:917-923. 10.3109/00365548.2010.511258, 20840000.
35. Collazos J, Asensi V, Carton JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 2007, 21:835-843. 10.1097/QAD.0b013e3280b0774a, 17415038.
36. Zaragoza-Macias E, Cosco D, Nguyen ML, Del RC, Lennox J. Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population. AIDS Res Hum Retroviruses 2010, 26:133-138. 10.1089/aid.2009.0001, 2858896, 20156096.
37. Currier J, Averitt BD, Hagins D, Zorrilla CD, Feinberg J, Ryan R, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med 2010, 153:349-357. 3056066, 20855799.
38. Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, et al. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis 2011, 203:442-451. 10.1093/infdis/jiq085, 3071223, 21245157.
39. Currier JS, Spino C, Grimes J, Wofsy CB, Katzenstein DA, Hughes MD, et al. Differences between women and men in adverse events and CD4 responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000, 24:316-324.
40. Nightingale SL. From the Food and Drug Administration. JAMA 1998, 280:1472. 10.1001/jama.280.17.1472, 9809716.
41. De SM, Carducci B, De SL, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002, 162:355. 10.1001/archinte.162.3.355, 11822931.
42. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med 2007, 4:106-119. 10.1016/S1550-8579(07)80025-8, 17707845.
43. Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009, 23:1689-1699. 10.1097/QAD.0b013e32832d3b54, 19487907.
44. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 2007, 21:2455-2464.
45. Andany N, Raboud JM, Walmsley S, Diong C, Rourke SB, Rueda S, et al. Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clin Trials 2011, 12:89-103. 10.1310/hct1202-89, 21498152.
46. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005, 191:825-829. 10.1086/428093, 15717255.
47. Spire B, Carrieri P, Garzot MA, L'henaff M, Obadia Y. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care 2004, 16:558-564. 10.1080/09540120410001716342, 15223524.
48. Squires KE, Johnson M, Yang R, Uy J, Sheppard L, Absalon J, et al. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother 2011, 66:363-370. 10.1093/jac/dkq457, 3019087, 21148235.
49. Falutz J. Management of fat accumulation in patients with HIV infection. Curr HIV/AIDS Rep 2011, 8:200-208. 10.1007/s11904-011-0087-3, 21739217.
50. Helleberg M, Engsig FN, Kronborg G, Larsen CS, Pedersen G, Pedersen C, et al. Retention in a public healthcare system with free access to treatment: a Danish nationwide HIV cohort study. AIDS 2012, 26:741-748. 10.1097/QAD.0b013e32834fa15e, 22156974.